Clinical Report: Exploring the Clinical Features and Treatment Approaches for Thyroid Lymphoma
Overview
This study analyzed 61 patients with thyroid lymphoma (TL), revealing that 67.2% had concurrent Hashimoto’s thyroiditis. Key findings include the impact of chemotherapy on prognosis and the identification of independent risk factors for shorter progression-free survival (PFS) in patients with thyroid diffuse large B-cell lymphoma (TDLBCL).
Background
Thyroid lymphoma is a rare malignancy that poses diagnostic challenges due to its non-specific clinical features and management controversies. The condition often coexists with Hashimoto’s thyroiditis, complicating treatment strategies. Understanding the clinical characteristics and optimal treatment approaches is crucial for improving patient outcomes.
Data Highlights
Outcome
1-Year OS
3-Year OS
5-Year OS
1-Year PFS
3-Year PFS
5-Year PFS
Rates
85.0%
78.4%
75.6%
76.5%
71.7%
63.1%
Key Findings
67.2% of patients had concurrent Hashimoto’s thyroiditis.
DLBCL was the most common histological subtype, accounting for 60.7% of cases.
Age ≥60 years and C-myc expression ≥50% were independent risk factors for shorter PFS in TDLBCL.
Chemotherapy was independently associated with improved PFS and OS.
Surgery alone without chemotherapy was linked to shorter PFS.
Clinical Implications
The findings underscore the importance of chemotherapy in improving survival outcomes for patients with TDLBCL. Clinicians should consider age and C-myc expression when assessing prognosis and tailoring treatment strategies for patients with thyroid lymphoma.
Conclusion
This study highlights the need for a multidisciplinary approach in managing thyroid lymphoma, particularly in patients with extrathyroidal involvement, to optimize treatment outcomes.
